LGD-4033 – Ligandrol

LGD-4033 Historical Development:

LGD-4033’s origins lie in the pioneering work of Ligand Pharmaceuticals, an organization renowned for its exploration of SARMs. In the early 21st century, researchers were on a relentless quest to find alternatives to anabolic steroids that could offer therapeutic benefits without the accompanying adverse effects. LGD-4033 was conceived and synthesized during this period, swiftly becoming one of the frontrunners among the emerging class of SARMs. With potential applications ranging from muscle wasting diseases to osteoporosis, LGD-4033 captured the attention of the scientific community.

Ligandrol Chemical Structure:

LGD-4033 boasts an intricate chemical structure. Central to LGD-4033 is a pyrrolidinyl group, which is linked to a trifluoro-substituted ether moiety. This is attached to a benzonitrile scaffold that has been further functionalized with a trifluoromethyl group. The chiral centers in the structure play a crucial role in its activity and specificity.

It’s important to note that LGD-4033 is non-steroidal. This distinction renders it structurally different from classical androgens, and consequently, it exhibits a different pharmacological profile.

Properties and Mechanism of Action:

LGD-4033 functions through selective binding and activation of the androgen receptor. By selectively targeting androgen receptors in muscle and bone tissues, LGD-4033 promotes anabolic activity without significantly impacting androgenic organs like the prostate. Its tissue-selective mechanism of action has the potential to prevent muscle wasting, promote muscle growth, and enhance bone mineral density.

To help convert LGD-4033 powder into a liquid version, we also offer PEG 400.

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.